For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
The idea of surrogate endpoints isn’t new, but they have matured with the increased adoption of accelerated pathways for regulatory approval. FDA will grant limited approval, but require confirmatory studies and as a result, sponsors need to prepare data and develop strategies earlier – for both regulators and payers.
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Why Rare Disease Therapeutics Need Early Market Access Planning
Jan 4, 2023
Three strategies for articulating a coherent product value story
Dec 18, 2021
Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs
Feb 8, 2022
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Overview of China's Market Approval Policy Med Insurance Payment System
Apr 7, 2022
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Preparing for a new era in European Market Access
Jul 22, 2022
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Use of AI to develop health economic evidence for optimized patient access
Sep 6, 2023
Are you using real-world evidence?
Feb 1, 2023